Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
iX BiopharmaSGX:42C +0.92%36 Current Ratio is 2.31 as of Mar. 2026, which is 43% below its 10-year median of 4.02. GuruFocus rates SGX:42C with a GF Score™ of 36/100 and a GF Value™ of S$0.03 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 999 Drug Manufacturers companies, iX Biopharma ranks better than 57.56% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. iX Biopharma's current ratio for the quarter that ended in Mar. 2026 was 2.31.
iX Biopharma has a current ratio of 2.31. It generally indicates good short-term financial strength.
The historical rank and industry rank for iX Biopharma's Current Ratio or its related term are showing as below:
SGX:42C'
s Current Ratio Range Over the Past 10 Years
Min: 0.47 Med: 4.02 Max: 12.88
Current: 2.31
During the past 12 years, iX Biopharma's highest Current Ratio was 12.88. The lowest was 0.47. And the median was 4.02.
SGX:42C's Current Ratio is ranked better than 57.56% of 999
companies
in the Drug Manufacturers industry
Industry Median: 1.97
vs SGX:42C: 2.31
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
iX Biopharma Current Ratio Related Terms
iX Biopharma Current Ratio Historical Data
* Premium members only.
The historical data trend for iX Biopharma's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SGX:42C vs ZTS, UTHR, VTRS: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, iX Biopharma's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
iX Biopharma Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, iX Biopharma's Current Ratio distribution charts can be found below:
* The bar in red indicates where iX Biopharma's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
iX Biopharma (SGX:42C) has a Current Ratio of 2.31 as of Mar. 2026. This is 43% below median its historical median of 4.02. Over the past decade, iX Biopharma's Current Ratio has ranged from 0.47 to 12.88. According to the industry distribution chart, iX Biopharma ranks #424 out of 999 companies in the Drug Manufacturers industry, placing it in the top 42.4%.
Is iX Biopharma's Current Ratio too high?
iX Biopharma's current Current Ratio of 2.31 is 43% below median its 10-year median of 4.02. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 12.88. The Drug Manufacturers industry median Current Ratio is 1.97. iX Biopharma's value of 2.31 is 17.3% above this industry median. Based on the distribution chart, iX Biopharma ranks #424 out of 999 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, iX Biopharma has a GF Score™ of 36/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does iX Biopharma's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, iX Biopharma ranks #424 out of 999 companies for Current Ratio. This puts iX Biopharma in the upper half of its industry. The industry median Current Ratio is 1.97. iX Biopharma's value of 2.31 is 17.3% above this benchmark. Historically, iX Biopharma's own Current Ratio has ranged from 0.47 to 12.88 over the past decade. While the company's 10-year median is 4.02 vs. the industry median of 1.97, iX Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 1.97, based on 999 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. iX Biopharma's current Current Ratio of 2.31 is 17.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 1.97 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. iX Biopharma's current Current Ratio is 2.31, which is 43% below median its own 10-year median of 4.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is iX Biopharma stock overvalued right now?
Based on GuruFocus' analysis, iX Biopharma (SGX:42C) is currently considered Significantly Overvalued. The stock's GF Value™ is S$0.03, compared to a current price of S$0.55 — trading 1733.3% above its estimated fair value. The current Current Ratio is 2.31, which is 43% below median its 10-year median of 4.02 and 17.3% above the Drug Manufacturers industry median of 1.97. iX Biopharma's overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For iX Biopharma (SGX:42C), the current Current Ratio is 2.31 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is iX Biopharma (SGX:42C) Overvalued in 2026?
Based on GuruFocus' analysis, iX Biopharma stock appears to be overvalued.
The current stock price of S$0.55 is trading 1733.3% above its estimated GF Value™ of S$0.03.
GuruFocus considers iX Biopharma to be Significantly Overvalued.
Key valuation signals for SGX:42C:
Current Ratio: 2.31 (43% below median its 10-year median of 4.02)
GF Value™: S$0.03 vs. price of S$0.55 (1733.3% above fair value)
Industry Position: 17.3% above the Drug Manufacturers median (#424 of 999)
No single metric tells the full story. See the SGX:42C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
iX Biopharma Ltd is a Singapore-based specialty pharmaceutical and nutraceutical company focused on the development, manufacture, and commercialization of therapies for the treatment of acute and breakthrough pain, and other health conditions. Its products under development are Wafermine and BnoX for pain management, Wafesil for erectile dysfunction, WafeRest for improved sleep quality, and others. Its business segments are the Specialty Pharmaceutical and Nutraceutical business segments. The firm's business segments operate in the United States of America, Singapore, Australia, and China, of which the majority of the revenue comes from the United States of America. The company generates the majority of its revenue from the sale of specialty pharmaceutical products.
36GF Score
Get the complete analysis for SGX:42C
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SGX:42C has been successfully added to your 
